Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Should You Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $67.15, but opened at $70.50. Zealand Pharma A/S shares last traded at $72.85, with a volume of 485 shares traded.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ZLDPF shares. Zacks Research upgraded shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 15th. Wells Fargo & Company raised shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Thursday, July 24th. Five research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Strong Buy”.

Zealand Pharma A/S Stock Up 6.9%

The stock has a market cap of $5.24 billion, a PE ratio of 5.18 and a beta of 0.71. The company has a debt-to-equity ratio of 0.02, a current ratio of 15.09 and a quick ratio of 15.08. The business has a fifty day moving average of $72.64 and a 200-day moving average of $65.63.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings data on Thursday, August 14th. The company reported $16.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $16.72 by ($0.66). The business had revenue of $1.43 billion for the quarter, compared to analysts’ expectations of $9.18 billion. Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 67.06%. Equities research analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.